<DOC>
	<DOCNO>NCT00228449</DOCNO>
	<brief_summary>The purpose study evaluate safety , pharmacodynamics ( PD ) , pharmacokinetics ( PK ) multiple intravenous dos peginesatide participant chronic kidney disease ( CKD ) hemodialysis .</brief_summary>
	<brief_title>Peginesatide Anemia Chronic Hemodialysis Patients</brief_title>
	<detailed_description>This Phase 2 , multicenter , open-label , sequential , dose-finding trial design 12 treatment cohort 15 participant per cohort . Each participant receive intravenous dose peginesatide administer every 4 week ( Q4W ) total 6 dos . Dosage regimens varied cohort . Participants follow minimum 42 day last administration peginesatide .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>Participant inform investigational nature study give write , witness informed consent accordance institutional , local , national guideline ; Males females ≥ 18 year age . Premenopausal female ( exception surgically sterile ) must negative pregnancy test screening ; sexually active must practice highly effective method birth control least 4 week prior study start , must willing continue contraception least 4 week last dose study drug . A highly effective method birth control define one result low failure rate ( i.e. , less 1 % per year ) use consistently correctly implant , injectables , combine oral contraceptive , intrauterine device ( IUDs ) , sexual abstinence ( acceptable practice lifestyle acceptable one sexually active practice abstinence duration study ) vasectomize partner ; Clinically stable hemodialysis ≥6 month prior study drug administration ; Urea clearance/volume ( Kt/V ) ≥ 1.2 within 4 week prior study drug administration ; Epoetin alfa maintenance therapy ≥ 60 ≤ 375 U/kg/wk continuously prescribe 8 week prior study drug administration . In last 3 week prior study drug administration , variation prescribe total weekly dose must ≤ 25 % mean last three prescribe total weekly dos ; Three mid endofweek hemoglobin value ≥ 10.0 ≤ 12.5 g/dL 3 week prior study drug administration ≤ 1.2 g/dL difference three value ; One serum ferritin level ≥ 100 microgram per liter ( μg/L ) one transferrin saturation ≥ 20 % one reticulocyte hemoglobin content ( CHr ) ≥ 29 picograms within 4 week prior study drug administration ; One serum folate level lower limit normal 4 week prior study drug administration ; One vitamin B12 level lower limit normal 4 week prior study drug administration ; Weight ≥ 45 kilogram ( kg ) within 4 week prior study drug administration ; One white blood cell count ≥ 3.0 x 10^9/L within 4 week prior study drug administration ; One platelet count ≥ 100 x 10^9/L ≤ 500 x 10^9/L within 4 week prior study drug administration . Known intolerance erythropoiesis stimulate agent ; History antibodies erythropoiesis stimulate agent history pure red cell aplasia ; Known intolerance parenteral iron supplementation ; Red blood cell transfusion within 12 week prior study drug administration ; Hemoglobinopathy ( e.g. , homozygous sicklecell disease , thalassemia type , etc . ) ; Known hemolysis ; Chronic , uncontrolled , symptomatic inflammatory disease ( e.g. , rheumatoid arthritis , systemic lupus erythematosus , etc . ) ; Creactive protein great 30 mg/L within 4 week prior study drug administration ; Moderate significant infection within 2 week prior study drug administration ; Known coagulation disorder base clinical context laboratory [ activate partial thromboplastin time ( aPTT ) international normalize ratio ( INR ) ] result ; Temporary ( untunneled ) dialysis access catheter ; Uncontrolled symptomatic secondary hyperparathyroidism ; Poorly control hypertension within 4 week prior study drug administration , per Investigator 's clinical judgment ( e.g. , systolic ≥ 170 mm Hg diastolic ≥ 100 mm Hg repeat reading ) ; Any history multiple significant drug allergy ; History severe unstable reactive airway disease within previous 10 year ; Epileptic seizure 6 month prior screen ; Chronic congestive heart failure ( New York Heart Association Class IV ) ; High likelihood early withdrawal interruption study ( e.g. , myocardial infarction , severe unstable coronary artery disease , stroke , respiratory , autoimmune , neuropsychiatric , neurological abnormality , liver disease include active hepatitis B C , active HIV disease , clinically significant medical disease condition prior 6 month may , Investigator 's opinion , interfere assessment followup patient ) ; Evidence malignancy within past 5 year ( except nonmelanoma skin cancer exclusion criterion ) ; Life expectancy &lt; 12 month ; Anticipated elective surgery study period ; Previous exposure investigational agent within 6 week prior administration study drug plan receipt study period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>anemia</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>CKD</keyword>
	<keyword>chronic renal failure</keyword>
	<keyword>CRF</keyword>
	<keyword>dialysis</keyword>
	<keyword>erythropoietin</keyword>
	<keyword>EPO</keyword>
	<keyword>erythropoiesis stimulating agent</keyword>
	<keyword>ESA</keyword>
	<keyword>Hematide™</keyword>
	<keyword>hemodialysis</keyword>
	<keyword>hemoglobin</keyword>
	<keyword>Hb</keyword>
	<keyword>Hgb</keyword>
	<keyword>Omontys</keyword>
	<keyword>peginesatide</keyword>
	<keyword>red blood cell</keyword>
	<keyword>red blood cell production</keyword>
</DOC>